285 related articles for article (PubMed ID: 16117725)
1. Comparison of the SUMO1 and ubiquitin conjugation pathways during the inhibition of proteasome activity with evidence of SUMO1 recycling.
Bailey D; O'Hare P
Biochem J; 2005 Dec; 392(Pt 2):271-81. PubMed ID: 16117725
[TBL] [Abstract][Full Text] [Related]
2. Stabilization of PML nuclear localization by conjugation and oligomerization of SUMO-3.
Fu C; Ahmed K; Ding H; Ding X; Lan J; Yang Z; Miao Y; Zhu Y; Shi Y; Zhu J; Huang H; Yao X
Oncogene; 2005 Aug; 24(35):5401-13. PubMed ID: 15940266
[TBL] [Abstract][Full Text] [Related]
3. Puromycin induces SUMO and ubiquitin redistribution upon proteasome inhibition.
Matsumoto H; Saitoh H
Biochem Biophys Res Commun; 2016 Jul; 476(3):153-8. PubMed ID: 27181354
[TBL] [Abstract][Full Text] [Related]
4. N4BP1 is a newly identified nucleolar protein that undergoes SUMO-regulated polyubiquitylation and proteasomal turnover at promyelocytic leukemia nuclear bodies.
Sharma P; Murillas R; Zhang H; Kuehn MR
J Cell Sci; 2010 Apr; 123(Pt 8):1227-34. PubMed ID: 20233849
[TBL] [Abstract][Full Text] [Related]
5. SUMOylation promotes PML degradation during encephalomyocarditis virus infection.
El McHichi B; Regad T; Maroui MA; Rodriguez MS; Aminev A; Gerbaud S; Escriou N; Dianoux L; Chelbi-Alix MK
J Virol; 2010 Nov; 84(22):11634-45. PubMed ID: 20826694
[TBL] [Abstract][Full Text] [Related]
6. Identification of RNF168 as a PML nuclear body regulator.
Shire K; Wong AI; Tatham MH; Anderson OF; Ripsman D; Gulstene S; Moffat J; Hay RT; Frappier L
J Cell Sci; 2016 Feb; 129(3):580-91. PubMed ID: 26675234
[TBL] [Abstract][Full Text] [Related]
7. Solubility shift and SUMOylaltion of promyelocytic leukemia (PML) protein in response to arsenic(III) and fate of the SUMOylated PML.
Hirano S; Tadano M; Kobayashi Y; Udagawa O; Kato A
Toxicol Appl Pharmacol; 2015 Sep; 287(3):191-201. PubMed ID: 26049103
[TBL] [Abstract][Full Text] [Related]
8. Modification of nuclear PML protein by SUMO-1 regulates Fas-induced apoptosis in rheumatoid arthritis synovial fibroblasts.
Meinecke I; Cinski A; Baier A; Peters MA; Dankbar B; Wille A; Drynda A; Mendoza H; Gay RE; Hay RT; Ink B; Gay S; Pap T
Proc Natl Acad Sci U S A; 2007 Mar; 104(12):5073-8. PubMed ID: 17360386
[TBL] [Abstract][Full Text] [Related]
9. Inhibiting ubiquitination causes an accumulation of SUMOylated newly synthesized nuclear proteins at PML bodies.
Sha Z; Blyszcz T; González-Prieto R; Vertegaal ACO; Goldberg AL
J Biol Chem; 2019 Oct; 294(42):15218-15234. PubMed ID: 31285264
[TBL] [Abstract][Full Text] [Related]
10. SUMOylation regulates the number and size of promyelocytic leukemia-nuclear bodies (PML-NBs) and arsenic perturbs SUMO dynamics on PML by insolubilizing PML in THP-1 cells.
Hirano S; Udagawa O
Arch Toxicol; 2022 Feb; 96(2):545-558. PubMed ID: 35001170
[TBL] [Abstract][Full Text] [Related]
11. REGgamma/PA28gamma proteasome activator interacts with PML and Chk2 and affects PML nuclear bodies number.
Zannini L; Buscemi G; Fontanella E; Lisanti S; Delia D
Cell Cycle; 2009 Aug; 8(15):2399-407. PubMed ID: 19556897
[TBL] [Abstract][Full Text] [Related]
12. Promyelocytic leukemia nuclear bodies provide a scaffold for human polyomavirus JC replication and are disrupted after development of viral inclusions in progressive multifocal leukoencephalopathy.
Shishido-Hara Y; Higuchi K; Ohara S; Duyckaerts C; Hauw JJ; Uchihara T
J Neuropathol Exp Neurol; 2008 Apr; 67(4):299-308. PubMed ID: 18379438
[TBL] [Abstract][Full Text] [Related]
13. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation.
Tatham MH; Geoffroy MC; Shen L; Plechanovova A; Hattersley N; Jaffray EG; Palvimo JJ; Hay RT
Nat Cell Biol; 2008 May; 10(5):538-46. PubMed ID: 18408734
[TBL] [Abstract][Full Text] [Related]
14. Loss of SUMO1 in mice affects RanGAP1 localization and formation of PML nuclear bodies, but is not lethal as it can be compensated by SUMO2 or SUMO3.
Evdokimov E; Sharma P; Lockett SJ; Lualdi M; Kuehn MR
J Cell Sci; 2008 Dec; 121(Pt 24):4106-13. PubMed ID: 19033381
[TBL] [Abstract][Full Text] [Related]
15. Three-dimensional organization of promyelocytic leukemia nuclear bodies.
Lang M; Jegou T; Chung I; Richter K; Münch S; Udvarhelyi A; Cremer C; Hemmerich P; Engelhardt J; Hell SW; Rippe K
J Cell Sci; 2010 Feb; 123(Pt 3):392-400. PubMed ID: 20130140
[TBL] [Abstract][Full Text] [Related]
16. Herpes virus induced proteasome-dependent degradation of the nuclear bodies-associated PML and Sp100 proteins.
Chelbi-Alix MK; de Thé H
Oncogene; 1999 Jan; 18(4):935-41. PubMed ID: 10023669
[TBL] [Abstract][Full Text] [Related]
17. Arsenic-induced SUMO-dependent recruitment of RNF4 into PML nuclear bodies.
Geoffroy MC; Jaffray EG; Walker KJ; Hay RT
Mol Biol Cell; 2010 Dec; 21(23):4227-39. PubMed ID: 20943951
[TBL] [Abstract][Full Text] [Related]
18. The PML-nuclear inclusion of human supraoptic neurons: a new compartment with SUMO-1- and ubiquitin-proteasome-associated domains.
Villagra NT; Navascues J; Casafont I; Val-Bernal JF; Lafarga M; Berciano MT
Neurobiol Dis; 2006 Jan; 21(1):181-93. PubMed ID: 16125395
[TBL] [Abstract][Full Text] [Related]
19. Proteasome-independent disruption of PML oncogenic domains (PODs), but not covalent modification by SUMO-1, is required for human cytomegalovirus immediate-early protein IE1 to inhibit PML-mediated transcriptional repression.
Xu Y; Ahn JH; Cheng M; apRhys CM; Chiou CJ; Zong J; Matunis MJ; Hayward GS
J Virol; 2001 Nov; 75(22):10683-95. PubMed ID: 11602710
[TBL] [Abstract][Full Text] [Related]
20. SUMO deconjugation is required for arsenic-triggered ubiquitylation of PML.
Fasci D; Anania VG; Lill JR; Salvesen GS
Sci Signal; 2015 Jun; 8(380):ra56. PubMed ID: 26060329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
